SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Virtus Convertible & Income 2024 Target Term Fund (CBH) trades at a trailing P/E of 25.5. Trailing earnings yield is 3.92%. PEG 0.11 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (60/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.11).
- PEG Ratio 0.11 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.92% — roughly competitive with bond yields (~4.3%), moderate risk-reward.
Overall SharesGrow Score: 69/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CBH
Valuation Multiples
P/E (TTM)25.5
Forward P/EN/A
PEG Ratio0.11
Forward PEGN/A
P/B Ratio0.00
P/S Ratio24.34
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.36
Book Value / Share$0.00
Revenue / Share$0.38
FCF / Share$0.00
Yields & Fair Value
Earnings Yield3.92%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$0.30 |
$9.96M |
$5.45M |
54.7% |
| 2018 |
$0.47 |
$9.19M |
$8.64M |
94% |
| 2019 |
$0.69 |
$13.15M |
$12.67M |
96.3% |
| 2020 |
$1.41 |
$26.25M |
$25.76M |
98.1% |
| 2021 |
$-0.02 |
$12.27M |
$-434K |
-3.5% |
| 2022 |
$0.11 |
$2.53M |
$2.11M |
83.6% |
| 2023 |
$0.36 |
$6.86M |
$6.54M |
95.4% |